vaccin
success
reduc
mortal
morbid
deliv
intramuscular
intraven
rout
associ
pain
babi
bring
lot
anxieti
parent
mark
increas
number
inject
requir
first
two
year
life
complet
vaccin
schedul
henc
need
painless
vaccin
deliveri
system
numer
new
rout
vaccin
like
oral
nasal
transderm
rout
tri
oral
polio
intranas
influenza
alreadi
success
newer
approach
like
edibl
vaccin
nasal
spray
dri
powder
prepar
jet
injector
microneedl
nanopatch
promis
deliv
painless
vaccin
mani
clinic
trial
vaccin
deliveri
system
painless
also
cost
effect
safe
easi
administ
mass
popul
may
devoid
need
cold
chain
painless
deliveri
system
ensur
better
complianc
vaccin
schedul
vaccin
cost
effect
way
decreas
mortal
morbid
due
variou
childhood
infecti
diseas
expand
programm
immun
epi
adopt
diphtheria
polio
tuberculosi
pertussi
measl
tetanu
prime
aim
immun
children
start
india
bcg
dpt
dose
typhoid
vaccin
opv
measl
vaccin
ad
list
subsequ
omiss
typhoid
vaccin
later
hepat
b
haemophilu
influenza
type
b
hib
includ
far
vaccin
success
erad
small
pox
polio
matern
neonat
tetanu
along
decreas
burden
mani
diseas
major
vaccin
avail
inject
prepar
child
receiv
mani
shot
vaccin
till
hesh
reach
age
two
accord
cdc
vaccin
schedul
besid
prototyp
oral
sabin
polio
vaccin
rotaviru
vaccin
cholera
vaccin
typhoid
vaccin
shigella
flexneri
vaccin
avail
oral
administr
nasal
spray
influenza
vaccin
also
avail
cdc
advisori
committe
abandon
use
flu
season
life
save
benefit
asid
thought
vaccin
come
pain
anxieti
associ
needl
prick
difficult
parent
handov
child
nurs
know
child
understand
hurt
helpless
feel
parent
know
discomfort
sideeffect
far
outweigh
morbid
mortal
due
diseas
common
vaccinerel
concern
parent
inject
pain
child
studi
kennedi
et
al
demonstr
parent
concern
pain
child
studi
suggest
nearli
parent
children
needl
fear
primari
reason
immun
noncompli
amongst
parent
children
pediatrician
must
ensur
vaccin
deliveri
painless
manner
guidelin
assist
clinician
manag
vaccinationrel
fear
pain
anxieti
among
children
reduc
pain
time
inject
breastfeed
administr
sweettast
solut
sucros
offer
rub
stroke
skin
near
inject
site
moder
intens
vaccin
parent
clinicianl
distract
use
topic
anesthet
lidocaineprilocain
cream
patch
amethocain
gel
liposom
lidocain
cream
tri
topic
applic
lidocaineprilocain
cream
proven
effect
interfer
immunogen
vaccin
parent
shown
good
accept
toward
even
though
expens
take
min
work
distract
defin
use
strategi
take
individu
attent
away
procedur
efficaci
variabl
music
seem
reduc
distress
pain
vaccin
adolesc
younger
children
howev
video
distract
reliev
anxieti
vaccin
pain
distract
blow
parti
blower
toy
reduc
vaccin
pain
children
parti
blower
also
aid
breath
techniqu
also
decreas
pain
breastfeed
reliev
pain
sweet
tast
distract
suckl
physic
contact
oral
sucros
solut
decreas
pain
releas
endogen
opioid
distract
tactil
stimul
form
pressur
site
reduc
pain
controversi
immun
procedur
matter
lot
parent
advis
hold
infant
comfort
place
supin
inject
vaccin
without
aspir
give
pain
vaccin
mmrii
prevnar
last
administ
multipl
vaccin
visit
reduc
pain
final
era
multipl
inject
parent
want
multipl
inject
given
simultan
rather
sequenti
insuffici
level
evid
reduc
pain
said
intervent
may
though
decreas
pain
fear
needl
anxieti
associ
procedur
vaccin
need
new
way
deliv
vaccin
need
hour
find
way
vaccin
deliveri
caus
pain
variou
vaccin
deliveri
method
alreadi
exist
painless
vi
vi
oral
nasal
vaccin
newer
noninvas
rout
administ
vaccin
follow
oral
nasal
aerosol
dri
powder
inhal
transderm
microneedl
nanopatch
consider
amount
exposur
infecti
agent
gut
mucosa
needl
vaccin
may
suffici
provid
protect
gut
infect
rout
initi
oral
vaccin
shun
consid
digest
small
fragment
gastric
enzym
render
ineffect
howev
oral
vaccin
made
use
lipid
fat
broken
stomach
travers
till
intestin
absorb
wellknown
oral
polio
vaccin
opv
use
mass
vaccin
campaign
due
eas
administr
trival
opv
consist
mixtur
live
attenu
polioviru
strain
three
serotyp
opv
produc
local
humor
immun
respons
antibodi
blood
protect
individu
polio
paralysi
prevent
spread
polioviru
nervou
system
local
immun
respons
line
mucou
membran
intestin
inhibit
multipl
subsequ
infect
wild
natur
occur
viru
also
stop
persontoperson
transmiss
wild
polioviru
nearli
india
free
polio
bival
opv
use
similar
oral
vaccin
avail
typhoid
efficaci
confer
protect
least
recipi
oral
liveattenu
vaccin
manufactur
strain
salmonella
serotyp
typhi
known
primari
vaccin
consist
entericco
capsul
taken
altern
day
day
total
four
capsul
present
vaccin
avail
use
india
oral
cholera
vaccin
ocv
singledos
live
oral
cholera
vaccin
two
oral
inactiv
nonliv
cholera
vaccin
proven
effect
epidem
outbreak
live
oral
cholera
vaccin
strain
cvd
attenu
live
vaccin
administ
singl
dose
efficaci
establish
global
ocv
stockpil
major
advanc
cholera
prepared
new
kill
liveattenu
vaccin
activ
explor
candid
vaccin
endem
set
andor
travel
vaccin
two
dose
current
avail
ocv
recommend
manufactur
singl
dose
would
easier
implement
qadri
et
al
prove
singledos
current
kill
oral
cholera
vaccin
prequalifi
world
health
organ
efficaci
epidem
rotaviru
respons
fever
nausea
vomit
wateri
diarrhea
young
infant
oral
vaccin
rotaviru
use
sinc
effect
brand
avail
vaccin
administ
oral
differ
number
dose
five
valent
vaccin
three
dose
requir
mo
mo
mo
monoval
human
strain
vaccin
requir
two
dose
mo
mo
edibl
vaccin
unusu
new
concept
scientist
suggest
plant
plant
virus
genet
engin
produc
vaccin
diseas
produc
introduc
select
gene
encod
bacteri
viral
antigen
plant
use
form
immunogen
protein
edibl
plant
vaccin
like
convent
subunit
vaccin
ie
immunogen
prepar
contain
antigen
protein
rather
pathogen
process
known
btransformationand
alter
plant
call
btransgen
plant
thu
highli
safe
caus
diseas
easi
administ
low
product
cost
elimin
need
ferment
purif
system
steril
deliveri
heat
stabl
requir
cold
chain
mainten
confer
mucos
iga
system
igg
immun
past
signific
progress
made
express
vaccin
antigen
edibl
leav
especi
lettuc
process
achiev
antigen
stabil
efficaci
prolong
storag
ambient
temperatur
grown
use
local
product
facil
thu
cut
expens
manufactur
cost
need
needl
prevent
infect
bioencapsul
antigen
plant
cell
protect
digest
system
fusion
antigen
transmucos
carrier
enhanc
effici
deliveri
immun
system
facilit
success
develop
plant
vaccin
oral
booster
antigen
express
plant
success
shown
ltb
etec
tobacco
potato
rabi
virusg
protein
tomato
hbsag
tobacco
potato
norwalk
viru
tobacco
potato
ctb
vibrio
cholera
potato
clinic
trial
undergo
malaria
measl
human
papilloma
viru
human
immunodefici
viru
respiratori
synctial
viru
mycobacterium
tuberculosi
human
clinic
trial
use
transgen
potato
cholera
toxin
shown
success
seroconvers
volunt
sublingu
rout
ie
via
mucos
surfac
tongu
buccal
rout
use
mani
year
deliv
drug
cardiovascular
drug
steroid
barbitur
benzodiazepin
opioid
analges
small
molecul
bloodstream
potenti
sublingu
buccal
vaccin
deliveri
larg
unexplor
superior
oral
vaccin
method
risk
degrad
gastric
enzym
similarli
skin
vaccin
method
imperm
thick
keratin
stratum
corneum
act
physiolog
barrier
chemic
disrupt
andor
microneedl
penetr
requir
sublingu
buccal
vaccin
deliveri
intranas
immun
also
induc
mucos
immun
retrograd
transport
antigen
andor
adjuv
vaccin
formul
brain
neural
tissu
caus
seriou
sideeffect
contrast
sublingu
rout
deliveri
wherein
antigen
migrat
central
nervou
system
occur
mani
laboratori
document
efficaci
sublingu
immun
induc
adequ
immun
respons
experiment
anim
system
use
varieti
antigen
includ
solubl
protein
inert
particul
antigen
kill
virus
viruslik
particl
bacteri
extract
well
liveattenu
virus
howev
clinic
trial
hpv
vaccin
appli
sublingu
human
antibodi
titr
lower
intramuscular
group
research
conclud
altern
deliveri
system
adjuv
would
requir
enhanc
evalu
immun
respons
follow
sublingu
immun
human
attract
option
vaccin
deliveri
effici
access
rel
clean
bmelt
mouth
stripsi
anoth
innov
vaccin
deliveri
research
mcmaster
univers
inspir
chemistri
consum
product
breathfreshen
strip
melt
tongu
pullulan
polysaccharid
deriv
common
fungu
key
ingredi
strip
normal
rest
solid
state
dissolv
easili
water
cast
enzym
substrat
within
materi
preserv
form
remain
inert
interact
water
undergradu
biomed
engin
student
john
hopkin
univers
develop
strip
lace
vaccin
rotaviru
respir
everi
moment
everi
breath
expos
sever
viral
bacteri
pathogen
transmit
airborn
particl
larg
surfac
area
respiratori
system
provid
adequ
interact
immun
system
antigen
nasal
mucosa
lung
consid
import
rout
vaccin
addit
extens
vascular
thin
epithelium
alveolar
lung
tissu
facilit
effici
system
deliveri
antigen
therebi
ensur
local
system
antibodi
deliveri
vaccin
via
rout
recent
emerg
attract
altern
inject
potent
practic
way
induc
effect
immun
infecti
diseas
elicit
rapid
immun
respons
local
system
gain
advanc
futur
selfadministr
noninvas
techniqu
thu
caus
littl
discomfort
patient
anoth
advantag
liquid
dri
powder
formul
given
thu
save
cost
spend
transport
via
cold
chain
variou
devic
avail
nasal
rout
vaccin
singl
dose
nasal
spray
bidos
nasal
spray
multidos
pump
tipseal
technolog
prevent
contamin
bottl
content
unitdos
nasal
powder
deliveri
system
bidos
nasal
powder
deliveri
system
jet
nebul
live
attenu
influenza
vaccin
call
laiv
may
given
healthi
nonpregn
peopl
age
nasal
spray
made
attenu
flu
viru
caus
flu
mani
flu
virus
keep
chang
everi
year
initi
believ
provid
protect
even
vaccin
match
current
season
viru
howev
recent
cdc
advisori
committe
immun
practic
acip
declar
use
flu
season
studi
conduct
show
protect
benefit
needlefre
nasal
immun
recombin
hbsag
use
nanoemuls
ne
also
prove
safe
effect
hepat
b
vaccin
provid
altern
booster
administr
parenter
hepat
b
vaccin
ne
nm
emuls
formul
surfact
distil
water
refin
soybean
oil
ethanol
solvent
initi
use
broadspectrum
antimicrobi
agent
ne
prove
effect
mucos
adjuv
whole
influenza
viru
vaccinia
virus
recombin
anthrax
protect
antigen
hiv
suzuki
et
al
develop
effici
nasal
vaccin
deliveri
system
pneumococc
infect
fuse
ctermin
fragment
clostridium
perfringen
enterotoxin
ccpe
pneumococc
surfac
protein
pspa
nasal
immun
pspaccp
induc
pspaspecif
igg
serum
bronchoalveolar
lavag
fluid
balf
well
iga
nasal
wash
balf
prove
suffici
protect
pneumococc
infect
nantachit
et
al
deliv
dengu
immunogen
domain
iii
dengu
e
protein
load
trimethyl
chitosan
nanoparticl
tmc
np
intranas
stimul
strong
local
innat
antivir
respons
help
system
adapt
immun
studi
also
conduct
ebola
viru
recent
dread
outbreak
western
africa
research
univers
texa
austin
develop
nasal
vaccin
provid
longterm
protect
nonhuman
primat
deadli
ebola
viru
result
small
preclin
studi
repres
proof
date
singl
dose
noninject
vaccin
platform
ebola
longlast
aerosol
vaccin
deliveri
involv
creat
small
particl
usual
gener
nebul
reach
lung
two
type
pulmonari
deliveri
devic
avail
use
vaccin
dri
powder
inhal
dpi
jet
nebul
pulmonari
vaccin
formul
hepat
b
viru
measl
tuberculosi
yersinia
pesti
preclin
research
phase
measl
vaccin
mmr
measl
mump
rubella
vaccin
bcg
vaccin
influenza
streptococcu
pneumonia
human
papilloma
viru
clinic
research
phase
clinic
trial
mexico
south
africa
demonstr
significantli
higher
rate
measl
seroconvers
follow
measl
vaccin
combin
rubella
measl
vaccin
children
aerosol
deliveri
subcutan
deliveri
anim
experi
also
demonstr
efficaci
mycoplasma
hyopneumonia
aerosol
vaccin
success
clinic
trial
done
use
jet
nebul
need
pressur
clean
air
system
stabil
concern
aqueou
vaccin
formul
limit
applic
mass
vaccin
program
product
powder
formul
pulmonari
administr
onestep
process
reduc
risk
contamin
batchtobatch
differ
well
product
cost
thu
simpl
cheap
compact
dispos
effect
dpi
optim
devic
pulmonari
vaccin
target
popul
skin
outermost
layer
call
stratum
corneum
lie
viabl
epidermi
compris
langerhan
cell
extrem
effect
antigenpres
cell
gener
immun
respons
vaccin
cutan
environ
rich
special
antigenpres
cell
use
microneedl
nanopatch
practic
immunolog
advantag
convent
needl
deliveri
microneedl
micro
structur
project
rang
solid
hollow
solid
microneedl
skin
pretreat
increas
skin
permeabl
ii
microneedl
coat
drug
dissolv
skin
iii
polym
microneedl
encapsul
drug
fulli
dissolv
skin
iv
hollow
microneedl
drug
infus
skin
volunt
clinic
studi
report
pain
minim
sensat
microneedl
array
like
due
enough
length
microneedl
stimul
nerv
present
deeper
tissu
microneedl
employ
success
vaccin
diphtheria
toxoid
adjuv
cholera
toxin
increas
deliveri
dna
vaccin
hepat
b
recombin
anthrax
vaccin
liveattenu
japanes
enceph
vaccin
anim
model
well
rabi
vaccin
human
subject
influenza
vaccin
coat
microneedl
shown
complet
protect
lethal
viral
infect
vaccin
use
season
strain
mice
substanti
improv
immun
result
follow
administr
bacillu
bcg
vaccin
guinea
pig
use
similar
coatedmicroneedl
devic
world
health
offici
aim
elimin
measl
microneedl
patch
game
changer
studi
levin
et
al
behren
et
al
confirm
immunogen
safeti
intraderm
deliveri
virosom
influenza
vaccin
vaccin
contain
heatlabil
toxin
escherichia
coli
travel
diarrhea
respect
human
nanopatch
np
compris
array
dens
pack
project
defin
geometri
distribut
design
physic
target
vaccin
directli
thousand
epiderm
dermal
antigen
present
cell
miniatur
array
smaller
standard
needl
use
vaccin
also
much
smaller
current
microneedl
array
np
immun
seen
effici
use
commerci
avail
influenza
vaccin
antigen
inactiv
whole
chikungunya
viru
vaccin
dnadeliv
attenu
west
nile
viru
vaccin
anoth
mode
vaccin
deliveri
known
via
jet
injector
jet
injector
needlefre
devic
deliv
prescrib
drug
vaccin
compound
intraderm
subcutan
intramuscularli
via
high
pressur
produc
either
carbondioxidefil
nitrogenfil
cartridg
spring
antigen
deliv
jet
injector
dispers
wide
tissu
high
pressur
fluid
stream
allow
larger
contact
volum
vaccin
antigen
immun
cell
sever
studi
shown
elicit
higher
antibodi
titer
seroconvers
rate
tradit
needl
syring
earlier
multiusenozzl
jet
injector
use
deliv
vaccin
fluid
stream
nozzl
multipl
patient
commonli
use
vaccin
militari
personnel
mass
immun
campaign
howev
year
wit
outbreak
hepat
b
infect
due
contamin
jet
injector
bodi
fluid
health
author
includ
depart
defens
world
health
organ
discontinu
use
multiusenozzl
jet
injector
nowaday
disposablecartridg
jet
injector
fluid
stream
deliv
within
dispos
vaccin
cartridg
nozzl
new
cartridg
nozzl
patient
splash
back
blood
develop
biovalv
miniject
bioject
powderject
develop
technolog
vaccin
trial
underway
deliv
inactiv
polio
vaccin
measlesmumpsrubella
vaccin
yellow
fever
vaccin
dtphibhep
b
vaccin
bcg
vaccin
rabi
vaccin
jet
inject
technolog
august
us
food
drug
administr
fda
approv
use
one
jet
injector
devic
pharmajetstrati
deliveri
one
particular
flu
vaccin
individu
age
howev
postvaccin
patient
report
tender
swell
pain
red
itch
bruis
site
vaccin
epiderm
powder
immun
epi
similar
liquid
jet
inject
driedpowd
particl
vaccin
rather
liquid
inject
skin
superson
speed
anoth
similar
concept
particlemedi
epiderm
deliveri
pmed
dna
vaccin
coat
gold
microparticl
shot
skin
clinic
studi
pmed
immun
promis
immunogen
respons
low
compar
convent
vaccin
method
whole
jet
inject
offer
multipl
benefit
less
pain
thu
improv
complianc
reduc
risk
needlestick
injuri
crosscontamin
elimin
need
bsharpsdispos
ensur
reliabl
reproduc
accur
deliveri
medic
minim
train
futur
immun
depend
success
abl
develop
method
vaccin
simpler
administ
need
cold
chain
mainten
provid
longlast
immun
respons
minim
sideeffect
importantli
childfriendli
way
needlefre
painless
vaccin
ensur
improv
safeti
vaccin
vaccine
commun
improv
complianc
immun
schedul
reduc
anxieti
pain
relat
inject
easier
speedier
vaccin
deliveri
reduc
cost
product
storag
transport
mean
less
healthcar
train
need
give
vaccin
especi
mass
vaccin
nation
subnat
immun
day
campaign
natur
pandem
bioterror
emerg
contribut
main
manuscript
prepar
ng
revis
critic
output
aa
aa
act
guarantor
paper
